PACB

PacBio is a long-read sequencing franchise trying to convert a growing Revio/Vega installed base into recurring consumables — and there are real green shoots: consumables revenue rose 16%, service revenue 36%, gross profit improved 23% to $45.8M (margin 28.6% vs prior year), and management is executing hard expense cuts (R&D -28%, SG&A -19%). But the top line is stalled at $160M (+3.9%), and the reason is structural, not transient: the MD&A attributes an 18% drop in Revio instrument revenue (61 units vs 97) to 'uncertainty surrounding the funding for new capital equipment, particularly among academic and research institutions.' The Risk Factors underscore reliance on 'academic, research and government institutions, which may be impacted by reductions in funding or targeted cancellations of certain grants.' With federal science funding under pressure, the instrument engine that seeds future consumables is running backward.

The balance sheet is what makes this uninvestable now. Stockholders' equity has been all but erased — $5.35M against $779M of liabilities (145x leverage) and a $2.70B accumulated deficit. The headline -$546M net loss is inflated by non-cash charges (notably $364.5M of acquired-intangible amortization and $15M impairment), so it overstates the bleed — but the cash truth is still grim: operating cash flow was -$111M against just $63.7M of cash. Even with the burn improving 46% and current assets of $375M providing a buffer, PacBio is spending well faster than its cash balance, and its own risk factors flag 'our ability to repay our debt and fund our long-term operations' and 'our stock price falling as a result of future offerings or sales of securities.' A dilutive raise at ~$1.68 looks close to unavoidable.